Open to all ACG 2018 attendees, Exhibitor Theaters are provided by ACG exhibitors. These presentations provide additional educational opportunities for attendees. No CME is provided for Theater presentations.
Rethinking Your Approach to Chronic Constipation: A Practical Understanding of CIC Pathophysiology
Sunday, October 7, 2018 | 6:15 pm – 7:00 pm
Kyle D. Staller, MD, MPH
Dr. Kyle Staller, Director of the Gastrointestinal Motility Laboratory at Massachusetts General Hospital will present an educational review of the underlying pathophysiological factors associated with chronic constipation requiring clinical management.
Sponsored by Shire Medical.
Treatments for the Proactive Management of IBS-D, IBS-C, and CIC Featuring New Phase 4 Data for a Treatment for IBS-D
Monday, October 8, 2018 | 10:30 am – 11:30 am
Brooks D. Cash, MD, FACG
This program is sponsored by Allergan & Ironwood.
Withstanding GI Reimbursement Pressures
Monday, October 8, 2018 | 12:45 pm – 1:20 pm
Jay Kreger & Mitch Guttenplan, MD
CRH offers both anesthesia partnerships and hemorrhoidal banding, offsetting reimbursement cuts in core GI businesses. Despite CMS cuts, CRH Anesthesia still provides supplemental income to your practice while raising patient satisfaction. The CRH O’Regan System®, utilized by 2,800 gastroenterologists nationwide, provides effective treatment of hemorrhoids with favorable margins, performed by gastroenterologists and advanced practitioners alike.
This program is sponsored by CRH Medical Corporation.
IBS-D: A Closer Look at Diagnosis, Microbial Imbalance and a Short-Term Treatment Option
Monday, October 8, 2018 | 1:40 pm – 2:15 pm
Mark Pimentel, MD, FRCP(C), FACG
Dr. Mark Pimentel, Executive Director, Medically Associated Science and Technology Program, Professor of Medicine, UCLA Geffen School of Medicine, and Associate Professor Cedars-Sinai Medical Center in Los Angeles, will provide a closer look at IBS-D - Diagnosis, Microbial Imbalance, and a Short-Term Treatment Option.
Sponsored by Salix Pharmaceuticals.
Expanding Options for Your Patients With OCALIVA®
Monday, October 8, 2018 | 3:45 pm – 4:45 pm
This program is sponsored by Intercept Pharmaceuticals.
A Treatment Option for Different Populations
Tuesday, October 9, 2018 | 10:35 am – 11:35 am
Laura Bamford, MD
Sponsored by Gilead.
Long-term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From IM-UNITI LTE Through 3 Years
Tuesday, October 9, 2018 | 12:45 pm – 1:20 pm
Stephen B. Hanauer, MD, FACG
Efficacy and safety results through 3 years (156 weeks) from the ongoing 5-year IM-UNITI long-term extension (LTE) study of subcutaneous (SC) Ustekinumab maintenance in moderate to severe Crohn’s disease.
Sponsored by Janssen Biotech, Inc.
Learn about a treatment for your patients with moderate to severe ulcerative colitis (UC) or Crohn's Disease (CD) who are ready to begin a biologic therapy
Tuesday, October 9, 2018 | 1:40 pm – 2:20 pm
Asher Kornbluth, MD
In this program, expert gastroenterologist Dr. Asher Kornbluth will discuss the mechanism of action and clinical profile of a therapeutic option for adult patients with moderate to severe UC or CD who are ready for a biologic.
Sponsored by Takeda Pharmaceuticals USA, Inc.